Leef Brands (LEEEF) Net Income towards Common Stockholders (2025 - 2026)
Leef Brands (LEEEF) reported Net Income towards Common Stockholders of -$426253.0 for Q1 2026, down 260.38% on a YoY basis from $265776.0 in Q1 2025, and down 260.38% sequentially from $265776.0 in Q1 2025.
Leef Brands (LEEEF) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends
Leef Brands (LEEEF) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$426253.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 260.38% year-over-year to -$426253.0; the trailing twelve-month figure through Mar 2026 stood at -$160477.0 (changed N/A YoY), and the FY2025 full-year result was -$17.6 million, up 28.77% from the prior year.
- Net Income towards Common Stockholders fell to -$426253.0 in Q1 2026, from $265776.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $265776.0 in Q1 2025 to a low of -$426253.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Leef Brands | 49.60 Mn | 43.84 Mn | 4.62 Mn | -426,253.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -426,253.00 |
| Mar 31, 2025 | 265,776.00 |